1.55Open1.55Pre Close0 Volume16 Open Interest2.50Strike Price0.00Turnover0.00%IV-13.23%PremiumOct 18, 2024Expiry Date1.66Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.51Leverage Ratio--Theta--Rho--Eff Leverage--Vega
BriaCell Therapeutics Stock Discussion
5 MINUTES AGO, 7:50 AM EDT
VIA GLOBENEWSWIRE
35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune check point inhibitor in metastatic breast cancer (MBC)
Primary endpoint is overall survival (OS) with Bria-IMT™ regimen plus Check Point Inhibitor (CPI) vs treatment of physician's choice
Interim data analysis planned at 144 eve...
Bria-IMT Combo Elicits Overall Survival Benefit in Metastatic Breast Cancer
No comment yet